Alpha 2.0
Login Register
» Authors » Keith D Dawkins

Keith D Dawkins

Explore the profile of Keith D Dawkins including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 145
Citations 4585
Followers 0
Related Specialties
Cardiology & Vascular Diseases
Pharmacology
General Medicine
Top 10 Co-Authors
Patrick W Serruys
Antonio Colombo
Marie-Claude Morice
Dominic J Allocco
Friedrich W Mohr
Gregg W Stone
Eberhard Grube
Michael J Mack
Elisabeth Stahle
Ian T Meredith
Published In
EuroIntervention
JACC Cardiovasc Interv
Am J Cardiol
J Am Coll Cardiol
Circulation
Affiliations
Soon will be listed here.
Recent Articles
1.
Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization
Takahashi K, Thuijs D, Gao C, Ono M, Holmes D, Mack M, et al.
Eur J Prev Cardiol . 2021 Feb; 29(2):312-320. PMID: 33624046
Aims: To evaluate the impact of various smoking status on 10-year all-cause mortality and to examine a relative treatment benefit of coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention...
2.
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial
Thuijs D, Kappetein A, Serruys P, Mohr F, Morice M, Mack M, et al.
Lancet . 2019 Sep; 394(10206):1325-1334. PMID: 31488373
Background: The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass...
3.
Clinical outcomes following implantation of the ION™ paclitaxel-eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. post-approval study
Cannon L, Kimmelstiel C, White A, Hill R, Grady T, Myers P, et al.
Catheter Cardiovasc Interv . 2019 Jan; 94(3):334-341. PMID: 30597737
Background: The ION Study assessed clinical outcomes for the thin-strut, ION™ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System (Boston Scientific, Marlborough, MA) in unselected patients. Methods: This prospective, open-label...
4.
Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial
Feldman T, Reardon M, Rajagopal V, Makkar R, Bajwa T, Kleiman N, et al.
JAMA . 2018 Jan; 319(1):27-37. PMID: 29297076
Importance: Transcatheter aortic valve replacement (TAVR) is established for selected patients with severe aortic stenosis. However, limitations such as suboptimal deployment, conduction disturbances, and paravalvular leak occur. Objective: To evaluate...
5.
Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial
Kelly C, Teirstein P, Meredith I, Farah B, Dubois C, Feldman R, et al.
JACC Cardiovasc Interv . 2017 Dec; 10(23):2392-2400. PMID: 29217001
Objectives: The authors sought to evaluate the final 5-year safety and effectiveness of the platinum-chromium everolimus-eluting stent (PtCr-EES) in the randomized trial, as well as in 2 single-arm substudies that...
6.
The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial
Milojevic M, Head S, Mack M, Mohr F, Morice M, Dawkins K, et al.
EuroIntervention . 2017 Nov; 14(1):102-111. PMID: 29155387
Aims: The aim of this study was to investigate short-term and five-year follow-up results from patients randomised to coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with paclitaxel-eluting...
7.
Impact of bioresorbable versus permanent polymer on longterm vessel wall inflammation and healing: a comparative drug-eluting stent experimental study
Wilson G, McGregor J, Conditt G, Shibuya M, Sushkova N, Eppihimer M, et al.
EuroIntervention . 2017 Aug; 13(14):1670-1679. PMID: 28846542
Aims: Drug-eluting stents (DES) have evolved to using bioresorbable polymers as a method of drug delivery. The impact of bioresorbable polymer on long-term neointimal formation, inflammation, and healing has not...
8.
A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study
Han Y, Liu H, Yang Y, Zhang J, Xu K, Fu G, et al.
EuroIntervention . 2017 Jul; 13(10):1210-1217. PMID: 28741576
Aims: The EVOLVE China randomised study sought to evaluate the clinical safety and effectiveness of the SYNERGY bioabsorbable polymer-coated everolimus-eluting stent (EES) for the treatment of patients with coronary heart...
9.
Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study
Falk V, Wohrle J, Hildick-Smith D, Bleiziffer S, Blackman D, Abdel-Wahab M, et al.
Eur Heart J . 2017 Jun; 38(45):3359-3366. PMID: 28651336
Aims: RESPOND is a prospective, open-label, single-arm study evaluating the outcomes following transcatheter aortic valve implantation (TAVI) with the repositionable and fully retrievable Lotus Valve used in routine clinical practice...
10.
Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients
Meredith I, Dumonteil N, Blackman D, Tchetche D, Walters D, Hildick-Smith D, et al.
EuroIntervention . 2017 May; 13(7):788-795. PMID: 28555592
Aims: The REPRISE IIE trial aimed to evaluate outcomes following transcatheter aortic valve implantation of the fully repositionable and retrievable LOTUS valve with a unique seal designed to minimise paravalvular...